Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeoX-101
- Development stage
- Unknown
- Lead developer
- LIXA
- Modality
- Small Molecules
- Administration
- Inhalation, Oral, Intravenous
01
Overview
NeoX-101 is a small-molecule antibiotic resistance breaker developed by Lixa. It utilizes the proprietary NeoX™ technology designed to 'switch off' bacterial resistance mechanisms via a conserved biological pathway, thereby potentially restoring the effectiveness of antibiotics against resistant strains. The drug is being evaluated in an inhaled formulation for chronic respiratory conditions, including bronchiectasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), having successfully completed a Phase 1 clinical trial. Additionally, oral and intravenous formulations are in preclinical development for the treatment of systemic infections.
Beyond the preview
Go deeper on NeoX-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoX-101.